Symbols / CRVS Stock $12.00 +2.21% Corvus Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NGM
CRVS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Richard A. Miller M.D.
Exch · Country NGM · United States
Market Cap 1.01B
Enterprise Value 751.34M
Income -44.17M
Sales —
FCF (ttm) -22.57M
Book/sh 2.86
Cash/sh 2.81
Employees 37
Insider 10d —
IPO Mar 23, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E -12.68
PEG —
P/S —
P/B 4.19
P/C —
EV/EBITDA -15.71
EV/Sales —
Quick Ratio 19.65
Current Ratio 19.81
Debt/Eq 0.35
LT Debt/Eq —
EPS (ttm) -0.55
EPS next Y -0.95
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -19.16%
ROE -30.46%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 84.09M
Shs Float 72.78M
Insider Own 3.51%
Instit Own 85.47%
Short Float 23.42%
Short Ratio 9.62
Short Interest 17.32M
52W High 26.95
vs 52W High -55.47%
52W Low 3.55
vs 52W Low 238.03%
Beta 0.84
Impl. Vol. 70.31%
Rel Volume 0.74
Avg Volume 1.49M
Volume 1.10M
Target (mean) $33.33
Tgt Median $31.50
Tgt Low $27.00
Tgt High $42.00
# Analysts 6
Recom Strong_buy
Prev Close $11.74
Price $12.00
Change 2.21%
About

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$33.33
Mean price target
2. Current target
$12.00
Latest analyst target
3. DCF / Fair value
$-4.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.00
Low
$27.00
High
$42.00
Mean
$33.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-17 init Goldman Sachs — → Buy $40
2026-03-13 reit Oppenheimer Outperform → Outperform $33
2026-01-22 main Jefferies Buy → Buy $42
2026-01-21 main Oppenheimer Outperform → Outperform $32
2026-01-21 main Barclays Overweight → Overweight $28
2026-01-20 main HC Wainwright & Co. Buy → Buy $27
2025-10-13 init Barclays — → Overweight $16
2025-05-20 main Mizuho Outperform → Outperform $11
2025-05-09 reit Oppenheimer Outperform → Outperform $17
2025-03-26 main Oppenheimer Outperform → Outperform $15
2025-03-26 reit HC Wainwright & Co. Buy → Buy $11
2025-01-14 reit HC Wainwright & Co. Buy → Buy $11
2025-01-02 init HC Wainwright & Co. — → Buy $11
2024-11-13 reit Oppenheimer Outperform → Outperform $14
2024-09-16 main Ladenburg Thalmann Buy → Buy $21
2024-05-07 main Oppenheimer Outperform → Outperform $8
2024-04-01 reit Cantor Fitzgerald — → Overweight —
2024-03-27 main Mizuho Neutral → Neutral $4
2024-03-20 main Oppenheimer Outperform → Outperform $7
2023-09-07 reit Cantor Fitzgerald Overweight → Overweight $4
News
RSS: Latest CRVS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-11 MOORE DAVID SCOTT Director — 21,700 $11.53 $250,236
2026-05-18 MILLER RICHARD A Chief Executive Officer — 6,932 $12.01 $83,453
2025-06-27 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 1,176,332 $4.16 $4,891,894
2025-06-27 THOMPSON PETER A Director and Beneficial Owner of more than 10% of a Class of Security — 1,176,332 $4.16 $4,891,894
2025-06-27 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 1,397,684 $3.50 $4,891,894
2025-06-27 THOMPSON PETER A Director and Beneficial Owner of more than 10% of a Class of Security — 1,397,684 $3.50 $4,891,894
2025-06-04 JONES WILLIAM BENTON Officer — 19,357 $3.50 $67,750
2025-05-07 MILLER RICHARD A Chief Executive Officer — 559,073 $3.50 $1,956,756
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
42.97
+55.99%
27.55
+17.69%
23.41
-28.12%
32.56
Research And Development
33.72
+73.94%
19.39
+17.30%
16.53
-32.46%
24.47
Selling General And Administration
9.25
+13.34%
8.16
+18.63%
6.88
-15.02%
8.10
General And Administrative Expense
9.25
+13.34%
8.16
+18.63%
6.88
-15.02%
8.10
Other Gand A
9.25
+13.34%
8.16
+18.63%
6.88
-15.02%
8.10
Total Expenses
42.97
+55.99%
27.55
+17.69%
23.41
-28.12%
32.56
Operating Income
-42.97
-55.99%
-27.55
-17.69%
-23.41
+28.12%
-32.56
Total Operating Income As Reported
-42.97
-55.99%
-27.55
-17.69%
-23.41
+28.12%
-32.56
EBITDA
-42.87
-56.09%
-27.46
-18.09%
-23.26
+27.77%
-32.20
Normalized EBITDA
-70.01
-1284.75%
5.91
+125.41%
-23.26
+27.82%
-32.22
Reconciled Depreciation
0.10
+23.53%
0.09
-43.71%
0.15
-58.86%
0.37
EBIT
-42.97
-55.99%
-27.55
-17.69%
-23.41
+28.12%
-32.56
Total Unusual Items
27.14
+181.33%
-33.37
0.00
-100.00%
0.02
Total Unusual Items Excluding Goodwill
27.14
+181.33%
-33.37
0.00
-100.00%
0.02
Special Income Charges
0.00
-100.00%
0.01
0.00
-100.00%
0.02
Net Income
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Pretax Income
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Net Non Operating Interest Income Expense
2.50
+37.34%
1.82
+15.15%
1.58
+142.20%
0.65
Interest Expense Non Operating
—
—
—
—
Net Interest Income
2.50
+37.34%
1.82
+15.15%
1.58
+142.20%
0.65
Interest Expense
—
—
—
—
Interest Income Non Operating
2.50
+37.34%
1.82
+15.15%
1.58
+142.20%
0.65
Interest Income
2.50
+37.34%
1.82
+15.15%
1.58
+142.20%
0.65
Other Income Expense
25.18
+168.86%
-36.57
-602.44%
-5.21
+44.59%
-9.40
Other Non Operating Income Expenses
—
—
0.08
-86.71%
0.59
Gain On Sale Of Security
27.14
+181.32%
-33.38
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Net Income From Continuing Operation Net Minority Interest
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Net Income From Continuing And Discontinued Operation
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Net Income Continuous Operations
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Normalized Income
-42.42
-46.69%
-28.92
-7.00%
-27.03
+34.60%
-41.33
Net Income Common Stockholders
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Diluted EPS
-0.53
+48.04%
-1.02
-82.14%
-0.56
+37.08%
-0.89
Basic EPS
-0.19
+81.37%
-1.02
-82.14%
-0.56
+37.08%
-0.89
Basic Average Shares
78.96
+29.48%
60.99
+26.99%
48.03
+3.16%
46.55
Diluted Average Shares
79.74
+30.76%
60.99
+26.99%
48.03
+3.16%
46.55
Diluted NI Availto Com Stockholders
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Earnings From Equity Interest
-1.96
+38.76%
-3.20
+39.50%
-5.28
+47.19%
-10.01
Gain On Sale Of PPE
0.00
-100.00%
0.01
0.00
-100.00%
0.02
Total Other Finance Cost
—
—
-1.58
-142.20%
-0.65
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
71.12
+3.21%
68.91
+51.27%
45.55
-33.25%
68.24
Current Assets
58.21
+7.00%
54.41
+94.62%
27.96
-35.97%
43.66
Cash Cash Equivalents And Short Term Investments
56.75
+9.21%
51.96
+91.40%
27.15
-35.82%
42.30
Cash And Cash Equivalents
4.58
-47.64%
8.74
-30.74%
12.62
-4.10%
13.16
Other Short Term Investments
52.17
+20.71%
43.22
+197.50%
14.53
-50.15%
29.14
Receivables
0.37
+73.15%
0.22
+242.86%
0.06
-90.05%
0.63
Accounts Receivable
0.04
-50.67%
0.07
+188.46%
0.03
-95.58%
0.59
Accrued Interest Receivable
0.34
+139.01%
0.14
+281.08%
0.04
-17.78%
0.04
Prepaid Assets
0.77
-54.02%
1.68
+220.42%
0.52
-16.29%
0.63
Other Current Assets
0.32
-41.97%
0.55
+149.09%
0.22
+115.69%
0.10
Total Non Current Assets
12.90
-11.00%
14.50
-17.60%
17.60
-28.40%
24.58
Net PPE
1.06
-20.26%
1.33
-4.12%
1.39
-46.11%
2.57
Gross PPE
3.71
-37.72%
5.95
-2.10%
6.08
-14.53%
7.12
Accumulated Depreciation
-2.65
+42.74%
-4.63
+1.51%
-4.70
-3.32%
-4.55
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
0.19
+11.11%
0.17
+0.00%
0.17
+20.42%
0.14
Other Properties
3.48
-5.79%
3.70
-3.34%
3.83
-21.74%
4.89
Leases
0.03
-98.42%
2.08
+0.00%
2.08
+0.00%
2.08
Investments And Advances
10.99
-12.35%
12.54
-22.22%
16.12
-26.30%
21.88
Long Term Equity Investment
10.99
-12.35%
12.54
-22.22%
16.12
-26.30%
21.88
Other Non Current Assets
0.85
+35.28%
0.63
+610.11%
0.09
-31.01%
0.13
Total Liabilities Net Minority Interest
9.91
-72.72%
36.34
+429.03%
6.87
-43.35%
12.12
Current Liabilities
9.38
-73.50%
35.40
+415.39%
6.87
-36.11%
10.75
Payables And Accrued Expenses
8.10
+55.79%
5.20
+13.84%
4.57
-44.67%
8.25
Payables
2.49
-3.52%
2.58
+69.31%
1.52
-22.82%
1.98
Accounts Payable
2.49
-3.52%
2.58
+69.31%
1.52
-22.82%
1.98
Current Accrued Expenses
5.61
+114.33%
2.62
-13.98%
3.04
-51.55%
6.28
Pensionand Other Post Retirement Benefit Plans Current
0.64
-21.83%
0.82
+19.88%
0.68
-38.54%
1.11
Current Debt And Capital Lease Obligation
0.40
+117.84%
0.18
-86.54%
1.37
+11.89%
1.23
Current Capital Lease Obligation
0.40
+117.84%
0.18
-86.54%
1.37
+11.89%
1.23
Other Current Liabilities
0.24
-99.18%
29.20
+11817.96%
0.24
+55.06%
0.16
Total Non Current Liabilities Net Minority Interest
0.53
-43.01%
0.94
0.00
-100.00%
1.37
Long Term Debt And Capital Lease Obligation
0.53
-43.01%
0.94
0.00
-100.00%
1.37
Long Term Capital Lease Obligation
0.53
-43.01%
0.94
0.00
-100.00%
1.37
Stockholders Equity
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Common Stock Equity
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Capital Stock
0.01
+0.00%
0.01
+40.00%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+40.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
74.70
+10.01%
67.90
+38.46%
49.04
+5.34%
46.55
Ordinary Shares Number
74.70
+10.01%
67.90
+38.46%
49.04
+5.34%
46.55
Additional Paid In Capital
474.39
+10.10%
430.86
+15.09%
374.36
+2.75%
364.36
Retained Earnings
-412.29
-3.85%
-397.01
-18.61%
-334.72
-8.78%
-307.69
Gains Losses Not Affecting Retained Earnings
-0.90
+30.43%
-1.29
-33.20%
-0.97
-71.76%
-0.56
Other Equity Adjustments
-0.90
+30.43%
-1.29
-33.20%
-0.97
-71.76%
-0.56
Total Equity Gross Minority Interest
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Total Capitalization
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Working Capital
48.83
+156.95%
19.00
-9.87%
21.09
-35.93%
32.91
Invested Capital
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Total Debt
0.94
-16.49%
1.12
-18.34%
1.37
-47.17%
2.60
Capital Lease Obligations
0.94
-16.49%
1.12
-18.34%
1.37
-47.17%
2.60
Net Tangible Assets
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Tangible Book Value
61.20
+87.93%
32.57
-15.81%
38.68
-31.06%
56.12
Duefrom Related Parties Current
—
—
—
0.59
Investmentsin Associatesat Cost
10.99
-12.35%
12.54
-22.22%
16.12
-26.30%
21.88
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-32.80
-29.00%
-25.42
-6.22%
-23.93
+11.43%
-27.02
Cash Flow From Continuing Operating Activities
-32.80
-29.00%
-25.42
-6.22%
-23.93
+11.43%
-27.02
Net Income From Continuing Operations
-15.28
+75.47%
-62.29
-130.47%
-27.03
+34.57%
-41.31
Depreciation Amortization Depletion
0.10
+23.53%
0.09
-43.71%
0.15
-58.86%
0.37
Depreciation And Amortization
0.10
+23.53%
0.09
-43.71%
0.15
-58.86%
0.37
Stock Based Compensation
5.33
+77.49%
3.00
+39.87%
2.15
-20.25%
2.69
Operating Gains Losses
-25.18
-168.86%
36.57
+592.07%
5.28
-47.07%
9.98
Gain Loss On Investment Securities
-27.14
-181.32%
33.38
—
—
Gain Loss On Sale Of PPE
0.00
+100.00%
-0.01
0.00
+100.00%
-0.02
Change In Working Capital
3.58
+317.30%
-1.65
+54.17%
-3.59
-354.53%
1.41
Change In Receivables
0.04
+177.55%
-0.05
-108.72%
0.56
+793.83%
-0.08
Changes In Account Receivables
0.04
+177.55%
-0.05
-108.72%
0.56
+793.83%
-0.08
Change In Prepaid Assets
0.94
+159.29%
-1.59
-19737.50%
-0.01
-101.38%
0.58
Change In Payables And Accrued Expense
2.67
+228.82%
0.81
+120.15%
-4.03
-558.88%
0.88
Change In Accrued Expense
2.76
+1226.94%
-0.24
+93.15%
-3.58
-866.17%
0.47
Change In Payable
-0.09
-108.61%
1.06
+334.37%
-0.45
-209.73%
0.41
Change In Account Payable
-0.09
-108.61%
1.06
+334.37%
-0.45
-209.73%
0.41
Change In Other Current Assets
0.12
+120.14%
-0.57
-151.53%
1.11
+2.59%
1.08
Change In Other Current Liabilities
-0.18
+26.59%
-0.25
+79.46%
-1.23
-17.30%
-1.05
Investing Cash Flow
-7.80
+71.63%
-27.48
-276.85%
15.54
+166.77%
-23.28
Cash Flow From Continuing Investing Activities
-7.80
+71.63%
-27.48
-276.85%
15.54
+166.77%
-23.28
Net PPE Purchase And Sale
-0.17
-3580.00%
0.01
+114.71%
-0.03
+86.23%
-0.25
Purchase Of PPE
-0.17
0.00
+100.00%
-0.03
+87.36%
-0.27
Sale Of PPE
0.00
-100.00%
0.01
0.00
-100.00%
0.02
Capital Expenditure
-0.17
—
-0.03
+87.36%
-0.27
Net Investment Purchase And Sale
-7.62
+72.27%
-27.49
-276.49%
15.57
+167.63%
-23.03
Purchase Of Investment
-91.75
-30.85%
-70.12
-49.04%
-47.05
+28.92%
-66.19
Sale Of Investment
84.13
+97.34%
42.63
-31.93%
62.62
+45.09%
43.16
Gain Loss On Sale Of Business
—
—
—
0.00
Financing Cash Flow
36.43
-25.70%
49.03
+524.16%
7.86
0.00
Cash Flow From Continuing Financing Activities
36.43
-25.70%
49.03
+524.16%
7.86
0.00
Net Common Stock Issuance
0.00
-100.00%
16.41
+109.17%
7.84
0.00
Proceeds From Stock Option Exercised
36.43
+11.67%
32.62
+271758.33%
0.01
0.00
Changes In Cash
-4.16
-7.32%
-3.88
-619.85%
-0.54
+98.93%
-50.30
Beginning Cash Position
8.74
-30.74%
12.62
-4.10%
13.16
-79.26%
63.46
End Cash Position
4.58
-47.64%
8.74
-30.74%
12.62
-4.10%
13.16
Free Cash Flow
-32.97
-29.68%
-25.42
-6.07%
-23.97
+12.18%
-27.29
Amortization Of Securities
-1.34
-17.88%
-1.14
-27.63%
-0.89
-425.88%
-0.17
Common Stock Issuance
0.00
-100.00%
16.41
+109.17%
7.84
0.00
Earnings Losses From Equity Investments
1.96
-38.76%
3.20
-39.50%
5.28
-47.19%
10.01
Issuance Of Capital Stock
0.00
-100.00%
16.41
+109.17%
7.84
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category